|Awarded On||February 21, 2018|
|Title||Targeting Stromal ERalpha for Cervical Cancer Therapy|
|Award Mechanism||Individual Investigator|
|Institution/Organization||University of Houston|
|Principal Investigator/Program Director||Sang-Hyuk Chung|
|Cancer Sites||Cervix Uteri|
Cervical cancer is the fourth most frequent cancer and the fourth leading cause of cancer death in women worldwide. Texas’ mortality rate of cervical cancer is 1.2-fold higher than the national average. It contrasts with that the mortality rate of all cancers is lower by 10% in Texas than the US. There has been little progress in the treatment of cervical cancer over the past decade, which accounts for the high cervical cancer mortality at present. Approximately 500,000 women contract the disease and 250,000 people die from it every year. It is clearly demonstrated that human papillomavirus (HPV) is required for the development of cervical cancer. Current HPV vaccines thus hold promise in pr...